Press Releases RegeneRx Biopharmaceuticals, Inc.

Equities

RGRX

US75886X3061

Delayed OTC Markets Other stock markets 01:13:48 2024-04-17 pm EDT			5-day change	1st Jan Change
0.0014 ^USD	-97.32%		0.00%	+16.67%

2023	RegeneRx Biopharmaceuticals, Inc. announced that it has received $0.05 million in funding from Essetifin S.p.A.	CI
2023	RegeneRx Biopharmaceuticals, Inc. announced that it expects to receive $0.175 million in funding	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations	23-08-16	AQ
RegeneRx Receives Stockholder Approval for Reverse Stock Split	23-08-07	PR
RegeneRx Biopharmaceuticals : Submission of Matters to a Vote of Security Holders - Form 8-K	23-08-07	PU
RegeneRx To Extend Consent Solicitation Vote	23-08-01	PR
RegeneRx Biopharmaceuticals, Inc. - First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical trial with RGN-259	23-04-14	AQ
First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259	23-04-13	PR
RegeneRx Issues Letter To Stockholders	23-04-11	PR
REGENERX BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operation. (form 10-K)	23-04-11	AQ
Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy	23-01-31	PR
Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy	23-01-03	PR
REGENERX BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-11-14	AQ
RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease	22-10-24	PR
RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy	22-09-28	AQ
RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)	22-09-27	PR
RegeneRx Issues 2022 Letter To Stockholders	22-08-22	PR
REGENERX BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-08-12	AQ
RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis	22-07-18	PR
RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259	22-06-22	PR
REGENERX BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-05-16	AQ
Tβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the Cornea	22-05-04	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases RegeneRx Biopharmaceuticals, Inc.

Equities

RGRX

US75886X3061

Press Releases

Filters